|drug1702||Intervention group_rehabilitation program Wiki||1.00|
There is one clinical trial.
Prospective interventional study, single arm of purified convalescent plasma transfusion as an add on therapy for the standard of care treatment (national guideline) (Oseltamivir (75mg/12 hours for 5-10 days) and hydroxychroquine (400mg twice in first day, 200 twice for 4-9 days) ± Azithromycin 500mg daily for 5 days
Description: Two successive negative COVID-19 PCR analysis tests 72 hours apartMeasure: viral COVID-19 clearance Time: 14 days
Description: The percentage of decrease of radiological abnormalities at day 14Measure: Decrease of radiological abnormalities Time: 14 days
Description: Clinical improvement in form of normal body temperature for 48 hoursMeasure: Clinical improvement Time: 14 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports